Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Shares Issued (2017 - 2025)

Catalyst Pharmaceuticals' Shares Issued history spans 14 years, with the latest figure at $1.9 million for Q4 2025.

  • For Q4 2025, Shares Issued changed N/A year-over-year to $1.9 million; the TTM value through Dec 2025 reached $14.7 million, down 90.03%, while the annual FY2025 figure was $14.7 million, 89.6% down from the prior year.
  • Shares Issued reached $1.9 million in Q4 2025 per CPRX's latest filing, down from $5.8 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $141.0 million in Q1 2024 to a low of $188000.0 in Q1 2021.
  • Average Shares Issued over 5 years is $9.9 million, with a median of $1.9 million recorded in 2024.
  • Peak YoY movement for Shares Issued: soared 11002.36% in 2024, then plummeted 96.6% in 2025.
  • A 5-year view of Shares Issued shows it stood at $685000.0 in 2021, then surged by 367.3% to $3.2 million in 2022, then tumbled by 93.75% to $200000.0 in 2023, then soared by 1900.0% to $4.0 million in 2024, then plummeted by 53.1% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Shares Issued are $1.9 million (Q4 2025), $5.8 million (Q3 2025), and $2.2 million (Q2 2025).